In Japan, the only drug available with reimbursement for acute HAE attacks in 2015 was plasma-derived C1-INH concentrate, whereas ecallantide and icatibant had not been approved for HAE treatment there [14]. This evidence concerns the gene SERPING1 and hereditary angioedema.